Today's guest is Gerard Quinn, Vice President of Innovation and Informatics at ICON plc. With over 35 years of experience in clinical research services, ICON is at the forefront of leveraging artificial intelligence to revolutionise the clinical trial process. In this episode, Gerard shares invaluable insights into how AI is reshaping the landscape of clinical trials, emphasising the importance of trust, scalability and evidence of value.Topics include:0:00 From pilot purgatory to scalable, data-driven AI deployment6:53 Focusing on delivering measurable, evidence-based, and trusted AI value10:43 Ensuring leadership buy-in through transparent, stepwise AI development15:54 Why AI adoption requires cultural and process change, not just implementation18:33 How AI accelerates tasks, enhances value and improves patient outcomes22:32 Optimizing trial sites, investigators and contract processes efficiently with AI27:23 How AI evolved from novelty to expectation, requiring careful implementation31:07 Managing AI adoption costs requires defined users and evidence of value35:02 Implementing AI requires strict governance, transparency, and regulatory compliance

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.